

GLAXOSMITHKLINE PLC  
Form 6-K  
February 20, 2019

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending 20 February 2019

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')
    - a) Name Mr J Ford
    - b) Position/status SVP & General Counsel
    - c) Initial notification/ amendment Initial notification
  2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
    - a) Name GlaxoSmithKline plc
    - b) LEI 5493000HZTVUYLO1D793
  3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
    - a) Description of the financial instrument GlaxoSmithKline plc American Depositary Shares ('ADSs')  
ISIN: US37733W1053
    - b) Nature of the transaction The exercise of options over 11,870 ADSs, granted on 22 February 2010 under the GlaxoSmithKline Share Option Plan, at an option price of \$37.32.
    - c) Price(s) and volume(s)
 

| Price(s) | Volume(s)                          |
|----------|------------------------------------|
| \$37.32  | 2,679 (Incentive Stock Option)     |
| \$37.32  | 9,191 (Non-Qualified Stock Option) |
- Aggregated information
- d) Aggregated volume 11,870
  - Price \$37.32
  - e) Date of the transaction 2019-02-19
  - f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr J Ford
  - b) Position/status SVP & General Counsel
  - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

GlaxoSmithKline plc American  
 Depository Shares ('ADSs')  
 ISIN: US37733W1053

|    |                           |   |                                    |
|----|---------------------------|---|------------------------------------|
| b) | Nature of the transaction | The sale of 11,870 ADSs, granted on 22 February 2010 under the GlaxoSmithKline Share Option Plan. |                                    |
|    |                           | Price(s)  | Volume(s)                          |
| c) | Price(s) and volume(s)    | \$41.22   | 2,679 (Incentive Stock Option)     |
|    |                           | \$41.22   | 9,191 (Non-Qualified Stock Option) |
|    | Aggregated information    |   |                                    |
| d) | Aggregated volume         | 11,870  |                                    |
|    | Price                     | \$41.22   |                                    |
| e) | Date of the transaction   | 2019-02-19  |                                    |
| f) | Place of the transaction  | New York Stock Exchange (XNYS)  |                                    |

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr J Ford
- b) Position/status SVP & General Counsel
- c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument ('ADSs')  
 GlaxoSmithKline plc  
 American Depository Shares  
 ISIN: US37733W1053

- b) Nature of the transaction The sale of ADSs
- c) Price(s) and volume(s)  
 Price(s) Volume(s)  
 \$41.22 11,884
- Aggregated information
- d) Aggregated volume n/a (single transaction)  
 Price
- e) Date of the transaction 2019-02-19
- f) Place of the transaction

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

New York Stock Exchange  
(XNYS)

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr J Ford
  - b) Position/status SVP & General Counsel
  - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882
  - b) Nature of the transaction Sale of Ordinary Shares
  - c) Price(s) and volume(s)

| Price(s) | Volume(s) |
|----------|-----------|
| £15.66   | 1         |

Aggregated information n/a (single transaction)
  - d) Aggregated volume  
Price
  - e) Date of the transaction 2019-02-19
  - f) Place of the transaction London Stock Exchange  
(XLON)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: February 20, 2019

By: VICTORIA WHYTE  
-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

